The interaction between CXCL12 and its receptor CXCR4 plays a crucial role in the homing and mobilization of haematopoietic progenitors. We investigated the putative association between a CXCL12 gene polymorphism, the G-A transition at position 801 in the 3 0 -untranslated region (3 0 UTR), and the yield of CD34 þ progenitors in 65 healthy allogeneic transplant donors who received G-CSF. Importantly, in this setting, the analysis was not biased by background disease or chemotherapy. The 3 0 UTR CXCL12 G801A polymorphism was detected using a PCR-RFLP technique with the MspI restriction enzyme and the frequency of CD34 þ progenitors was assessed by flow cytometry. The frequency as well as the number of CD34 þ progenitor cells in the first leukapheresis product was significantly higher from donors with the CXCL12-3 0 A allele compared to GG homozygotes (Po0.05 in both cases), especially for subjects with the CXCL12-3 0 AA homozygous genotype (Po0.01 in both cases). Moreover, more leukaphereses were needed to obtain the required number of CD34 þ progenitors for transplantation from CXCL12-3 0 GG homozygous donors compared to the CXCL12-3 0 A carriers (P ¼ 0.003). In conclusion, the CXCL12-3 0 A allele was associated with a higher yield of CD34 þ cells from healthy donors of PBPC for allogeneic haematopoietic SCT.
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Introduction
Peripheral blood mobilized by cytokines and chemotherapy has become a major source of haematopoietic stem and progenitor cells for autologous transplantation as well as for an increasing number of allogeneic transplantations. [1] [2] [3] [4] However, the mechanisms that underlie the migration of stem cells from the BM to the peripheral blood remain unclear.
Stromal cell-derived factor-1 (SDF-1/CXCL12 (CXC motif, ligand 12)), a member of the CXC chemokine family, is secreted by the BM stroma under physiological conditions and during BM regeneration following myeloablative therapy given before transplantation. 5, 6 This chemokine plays a key role in haematopoiesis: the homing, migration and survival of haematopoietic progenitors, and the mobilization of haematopoietic progenitors from the BM (reviewed in references 4, 7 ). There are at least six isoforms of CXCL12 (a, b, g, d, e and f), which are produced by alternative splicing. [8] [9] [10] The physiological receptors of CXCL12 are CXCR4 and CXCR7, 8 but only CXCR4 is involved in haematopoiesis. CXCR4 is a G-protein-coupled seven-transmembrane receptor present on the CD34 þ cells. The CXCL12 gene is located on human chromosome 10q11.1, whereas the other CXC/a chemokines are encoded by chromosome 4q. Sequence analyses have revealed a common polymorphism in the 3 0 -untranslated region (3 0 UTR; a G-A transition at position 801, designated CXCL12-3 0 UTR-801-G-A), that has been implicated in the regulation of the turnover of the CXCL12b transcript.
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The first clinical association of the CXCL12 G801A polymorphism, the slower progression to AIDS in late stage of HIV-1 infection in AA homozygous individuals, was described by Winkler et al. 11 They also hypothesized that CXCL12-3 0 A genotype may increase the amount of CXCL12 protein available to bind CXCR4.
The interaction between CXCL12 and CXCR4 plays a crucial role in the homing and mobilization of haematopoietic progenitors. The mobilization of haematopoietic stem cells from the BM to the peripheral circulation can be induced by G-CSF. It has been postulated that the degradation of CXCL12 by granulocyte enzymes that are activated by G-CSF plays a role in the mobilization process. 3, 12 On the other hand, we have previously demonstrated the role of the membrane density of CXCR4 on CD34 þ cells in G-CSF-induced mobilization in humans. 13 Additionally, Christopherson et al.
14 have demonstrated that the mechanism of action underlying the G-CSF-mobilization of haematopoietic stem cells in a murine system also involves the activity of CD26, an extracellular peptidase, suggesting that this process is more complex. Moreover, a study by Benboubker et al. 15 has shown that the CXCL12 gene polymorphism may influence the egress of CD34 þ cells to the peripheral blood in patients mobilized for autologous transplantation.
The aim of this study was to investigate the putative association between the CXCL12 gene polymorphism and the yield of CD34 þ progenitor cells from healthy donors receiving G-CSF only. In this setting, the analysis was not biased by background disease and/or chemotherapy.
Materials and methods

Individuals studied
The G-A transition at position 801 in the 3 0 UTR of the CXCL12 gene and the number of haematopoietic progenitor cells was analysed in 65 healthy donors of allogeneic transplants (female/male ¼ 31/34; age range 8-65 years, median 35 years). This study was approved by the Local Ethics Committee and informed consent was obtained from all the donors studied. The male (8-65 years, median 35 years) and female (13-54 years, median 35 years) donors did not differ with respect to age. There were 15 and 14 patients over the median age among the female and male donors, respectively. All donors received G-CSF (Neupogen, Filgrastim; Roche, Basel, Switzerland), usually at a dose of 5 mg per kg bodyweight twice daily beginning 5 days before the first leukapheresis. The G-CSF administration was continued if a second leukapheresis was needed. Leukaphereses were performed using a COBE Spectra continuous flow separator (COBE BCT; Blood Component Technology, Lakewood, CO, USA).
Enumeration of CD34 cells
A FACS Calibur flow cytometer (Becton Dickinson, Mountain View, CA, USA) was used for the detection and enumeration of CD34 þ cells in the leukapheresis products. That data acquisition and analysis were performed using Cellquest and PC-Lysis (Version 1.0) software (BD). The Leuco-GATE Monoclonal (Mo) Abs mixture (CD45 FITC/CD14 PE) was used to gate pure leukocyte populations. A PerCP-conjugated anti-CD34 (Clone 8G12) MoAb was used to detect progenitor cells and a PerCP-conjugated Mouse IgG1 was used as an isotype control (all MoAbs were purchased from Becton Dickinson, Erembodegen, Belgium).
CXCL12 gene polymorphism DNA was extracted from peripheral blood taken on EDTA using silica membranes (the QIAmp Blood Kit; Qiagen, Hilden, Germany) following the recommendation of the manufacturer.
The. 3 0 UTR CXCL12 G801A polymorphism was analysed using a PCR-RFLPassay, which amplified a fragment of the 3 0 UTR of the gene using primers previously described by Winkler et al. 
Statistical analysis
Statistical evaluation was performed using the unpaired t-test or the Fisher's exact test for nonparametric distribution using Microsoft Excel and Statistica 5.5 for Windows software, respectively. Any differences between samples were considered significant if Po0.05. In addition, the Statistical Package for Social Scientists (SPSS, SYSTAT 10) was used for multivariate logistic regression analysis.
Results
Distribution of CXCL12 genotypes
Among the 65 individuals examined, 4, 24 and 37 were genotyped as CXCL12-3 0 AA (6. 2%), AG (36.9%) and GG (56.9%), respectively ( Table 1 ). The allelic frequencies were 0.246 for CXCL12-3 0 A and 0.754 for CXCL12-3 0 G. This distribution of CXCL12 alleles and genotypes closely resembles a previously described distribution observed in other studies of similar populations. 16 A significant difference was observed in the distribution of the AG and GG genotypes among the male and female donors. The male donors had a higher frequency of the AG genotype (50.0% in male donors vs 22.6% in female donors, P ¼ 0.020) and a decreased frequency of the CXCL12-3 0 -A allele (55.9 vs 29.1%, P ¼ 0.026).
Relationship between the CD34 þ cell yield and the CXCL12 genotype The percentage of CD34 þ progenitor cells in the first leukapheresis product was associated with the 3 0 UTR CXCL12 G801A polymorphism. The frequency of CD34 þ progenitor cells in the first leukapheresis product was significantly higher in donors with the CXCL12-3 0 A CXCL12 gene polymorphism and mobilization potential K Bogunia-Kubik et al allele as compared to the GG homozygotes (median: 0.800 vs 0.570%, P ¼ 0.029; Figure 1a ). Significant differences were also seen in donors with the CXCL12-3 0 AA homozygous genotype as compared to donors with the AG genotype (median: 1.035 vs 0.785%, P ¼ 0.012) or the GG genotype (1.035 vs 0.570%, P ¼ 0.007; Figure 1a) . Thus, donors with the CXCL12-3 0 A allele, especially the CXCL12-3 0 AA homozygous individuals (1.035 vs 0.620%, P ¼ 0.008 for AA and G individuals, respectively), had a better mobilization potential.
Similar relationships were observed when the number of WBC or CD34 þ cells per ml of the leukapheresis product was compared in donors with the different CXCL12 genotypes. A higher concentration of CD34 þ cells in the first leukapheresis product was detected in CXCL12-3 0 Apositive donors compared to GG homozygous donors (median: 1.245 Â 10 3 vs 0.806 Â 10 3 of CD34 cells per ml of leukapheresis product, P ¼ 0.018; Figure 1b ). Significant differences were also observed in donors with the CXCL12- There was a significant difference in the distribution of the AG and GG genotypes among the male and female donors. Male donors had a higher frequency of AG and A genotypes. a Indicates the differences in the distribution of AG genotypes in female and male donors. b Indicates the difference in the distribution of genotypes containing the A allele between both groups of donors tested.
In addition, the WBC concentration was significantly higher in donors with the CXCL12-3 0 A allele compared to the GG homozygous donors (median: 199.5 Â 10 3 vs 158.6 Â 10 3 of WBCs per ml of leukapheresis product, P ¼ 0.032). This association was significant when the AA homozygous donors were compared to the AG (median: 518.0 Â 10 3 vs 178.4 Â 10 3 cells per ml, P ¼ 0.019) or GG donors (518.0 Â 10 3 vs 158.6 Â 10 3 cells per ml, Po0.001).
Association of the CXCL12-3 0 A allele with a lower number of leukaphereses To obtain the required number of CD34 þ progenitors for transplantation, usually one to three leukaphereses are performed. However, for all four CXCL12-3 0 AA homozygous donors only one leukapheresis was performed. For 19, 4 and 1 of the donors with the CXCL12-3 0 AG heterozygous genotype, 1, 2 and 3 leukaphereses were performed, respectively. Two or three leukaphereses were required for the CXCL12-3 0 GG homozygous donors (15 and 5 subjects, respectively) and the differences in the number of leukaphereses performed was significant for the CXCL12-3 0 GG homozygous donors when compared to donors with the CXCL12-3 0 A allele. Of the 33 donors with the CXCL12-3 0 GG homozygous genotype, 20 had 2 or 3 leukaphereses, whereas only 5 of 25 donors with the CXCL12-3 0 A allele required more than 1 leukapheresis (54 vs 18%, P ¼ 0.003; Figure 2 ).
Relationship between donor age and gender and the mobilization potential of CD34
þ progenitor cells A higher mobilization potential was observed in younger donors (p35 years old) when compared to the older donors (median frequency of CD34 þ cells in the first leukapheresis product: 0.785 vs 0.580%, P ¼ 0.089) and it was significantly higher in male donors compared to female donors (0.800 vs 0.570%, P ¼ 0.028). The latter relationship may result from the observed differences in the distribution of the CXCL12 alleles in the analysed individuals. The CXCL12-3 0 A allele, which is associated with an increased percentage of CD34 þ progenitor cells mobilized to the peripheral blood, was more frequently detected in male donors (Table 1) . No significant differences between the number of WBCs or CD34 þ cells per ml of the first leukapheresis product were observed when the donors were separated based on age or gender.
Multivariate analysis of the factors associated with the mobilization capacity To determine if the CXCL12-3 0 A allele constitutes an independent factor associated with (1) better CD34 þ cell mobilization (expressed either as the frequency or the total number of CD34 þ progenitor cells in the first leukapheresis product that exceeded the median value) and (2) Thus, the multivariate analyses suggest that the CXCL12-3 0 A allele is a significant and independent factor that affects the mobilization capacity of donor haematopoietic stem cells.
Discussion
Accumulating evidence suggests that the interaction of CXCL12 with CXCR4 induces signals that regulate haematopoietic progenitor cell trafficking in the BM. 3, 12, 17 During G-CSF-induced haematopoietic progenitor cell mobilization, the expression of CXCL12 in the BM decreases. G-CSF decreases the level of CXCL12 within the BM through the degradation of CXCL12 by proteolytic enzymes that are released by neutrophils during mobilization. 12 On the other hand, it has been demonstrated that the higher concentration of CXCL12 in the peripheral circulation facilitates the mobilization of CD34 cells in mice. Hattori et al. 18 have reported that the overexpression of CXCL12 in the peripheral circulation (for example, the i.v. injection of an recombinant adenovirus expressing CXCL12) results in the mobilization of haematopoietic cells with repopulating capacity, progenitor cells and precursor cells.
In this study, we examined the effect of the CXCL12-3 0 A allele on the mobilization of haematopoietic progenitor cells in healthy individuals donating blood for allogeneic transplants. Indeed, Benboubker et al. 15 have demonstrated that the CXCL12 gene polymorphism may influence the egress of CD34 cells to the peripheral blood in patients mobilized for autologous transplantation. However, all of the patients analysed in that study received chemotherapy before, or during, mobilization that could affect the number of haematopoietic progenitors mobilized to peripheral blood. Therefore, in this work we investigated the putative association between the CXCL12 gene polymorphism and the mobilization yield in healthy donors receiving CXCL12 gene polymorphism and mobilization potential K Bogunia-Kubik et al G-CSF only. Therefore, our analysis was not biased by either background disease or chemotherapy. We observed an association between the 3 0 UTR CXCL12 G801A polymorphism and better CD34 þ cell mobilization (expressed as either the percentage or total number of CD34 þ progenitor cells in the first leukapheresis product) and a higher efficacy of leukapheresis (that is, a lower number of leukaphereses performed to obtain the required number of CD34 þ progenitors for transplantation). The higher mobilization potential characterized healthy donors with the CXCL12-3 0 A allele, especially the CXCL12-3 0 AA homozygous individuals.
The association of the CXCL12-3 0 A allele with the higher frequency or number of CD34 þ progenitors in the first leukapheresis product was confirmed by multivariate analyses, in which the CXCL12 genotype was shown to be an independent factor affecting mobilization.
Interestingly, a similar distribution of CXCL12 genotypes was seen in this study and in our preliminary study involving patients undergoing autologous haematopoietic SCT. 19 Similar to this study, a significantly higher frequency of CD34 þ progenitor cells was seen in the first leukapheresis product from patients with the CXCL12-3 0 A allele when compared to the GG homozygous individuals. In addition, these results correspond with our observations in lymphoma patients (with either the GG or GA genotypes) who failed to have a sufficient number of CD34 þ cells for autologous transplantation, in spite of three leukaphereses performed (unpublished results). Thus, our results regarding patients undergoing autologous transplantation of haematopoietic stem cells concur with those reported by Benboubker et al.
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The association between the CXCL12 gene polymorphism and the serum levels of CXCL12vwas suggested by Winkler et al. 11 However, to date, the exact relationship between the CXCL12 genotypes and the corresponding protein production is not clear and the studies examining the association differ in their methodological approaches. [20] [21] [22] [23] As this mutation lies in the 3 0 UTR of the gene, Winkler et al.
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suggested that this mutation may upregulate transcription of the gene, resulting in more abundant CXCL12, which in turn, inhibits T-tropic HIV-1 and delays the onset of the disease. Arya et al. 20 tested this hypothesis in vitro: the wild-type and the mutant CXCL12 gene were cloned and the expression was measured in human and insect cells in culture. However, in their study, the mutation in the 3 0 UTR did not affect RNA synthesis in vitro.
Similarly, Kimura et al. 21 did not detect a significant association between the CXCL12 gene polymorphism and gene expression (CXCL12 mRNA levels) in EBV-transformed lymphoblastic cell lines. Their more recent study 22 on EBV-transformed lymphoblastic cell lines with a heterozygous CXCL12 genotype demonstrated that the polymorphisms other than the CXCL12 G801A polymorphism could have a cis-acting effect on the expression of CXCL12 transcripts.
In fact, an association between CXCL12-3 0 AA homozygosity and low plasma CXCL12 levels in HIV-exposed, but uninfected, persons was reported by Soriano et al. 23 Moreover, Signoret et al. 24 showed that the increased secretion of the CXCL12 may downmodulate CXCR4 on
CD34
þ cells, a phenomenon that, in turn, prevents the homing of haematopoietic progenitors to the BM. Indeed, we and others 13, 25, 26 have observed a negative correlation between the mobilization capacity and CXCR4 expression on CD34 þ cells. Our previous study demonstrated that the number of haematopoietic progenitors in the peripheral blood correlated with the percent of CXCR4-negative CD34 þ cells in the leukapheresis product. 13 In light of these observations, we hypothesize that the concentration of CXCL12 within the BM following administration of G-CSF is affected by a polymorphism within the CXCL12 gene (the CXCL12-3 0 A allele is associated with a lower CXCL12 protein production as reported by Soriano et al. 23 ). This decreased concentration of CXCL12 may facilitate the egress of CD34 þ cells to the peripheral circulation. Moreover, these results suggest that the better efficacy of CD34 þ cell mobilization from the BM to the peripheral circulation is associated with a positive gradient of CXCL12 between the BM and the peripheral blood and the higher concentration of CXCL12 in peripheral blood downmodulates CXCR4 expression on CD34 þ cells. 24 This concurs with the results of our previous report describing an increased number of CD34 þ cells lacking CXCR4 expression in the leukapheresis product. 13 In this study, we also observed a relationship between the higher mobilization yield of CD34 þ cells and the donor's age and gender. A higher mobilization potential was characteristic of the younger donors and the male donors. Obviously, these results need to be confirmed in a larger cohort of allogeneic donors. The association between mobilization potential and gender could be attributed to the influence of sex hormones. It has been recently demonstrated that sex hormones can alter cytokine production and lipopolysaccharide-stimulated mononuclear cells from male donors have been reported to produce higher mRNA levels of TNF and IL-10 compared to female donors. 27 This could be also true for other cytokines and chemokines, including CXCL12, and warrants further study. In summary, the CXCL12-3 0 A allele was found to be associated with a higher yield of CD34 þ cells from healthy donors of PBPC for allogeneic haematopoietic SCT. This finding may help to optimize the mobilization strategies in individuals donating PBPC for transplantation.
